ArticleEmerging infectious diseases2006
Antibody response to Pneumocystis jirovecii major surface glycoprotein.
Article in Emerging infectious diseases, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Advances in pathogen detection ofInfectious medicine · 2025Review
- Pathogenic microorganism detection in AIDS patients using bronchoalveolar lavage fluid.International journal of clinical and experimental pathology · 2020Article
- A Molecular Window into the Biology and Epidemiology of Pneumocystis spp.Clinical microbiology reviews · 2018Review
- The Interaction ofJournal of immunology (Baltimore, Md. : 1950) · 2017Article
- Article
- Review
- Antibody responses against Pneumocystis jirovecii in health care workers over time.Emerging infectious diseases · 2013Article
- Colonization by Pneumocystis jirovecii and its role in disease.Clinical microbiology reviews · 2012Review
- Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms.PloS one · 2012Article
- Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia.Journal of acquired immune deficiency syndromes (1999) · 2011Article
- Decreased serum antibody responses to recombinant pneumocystis antigens in HIV-infected and uninfected current smokers.Clinical and vaccine immunology : CVI · 2011Article
- Article
- Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2010Article
- Healthcare worker occupation and immune response to Pneumocystis jirovecii.Emerging infectious diseases · 2009Article
- Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection.The Journal of infectious diseases · 2009Article
- Pneumocystis workshop: 10th anniversary summary.Eukaryotic cell · 2009Article
- Pneumocystis colonization in immunocompetent and simian immunodeficiency virus-infected cynomolgus macaques.The Journal of infectious diseases · 2009Article
- Relationship of pneumocystis antibody response to severity of chronic obstructive pulmonary disease.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2008Article
- Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
We conducted a prospective pilot study of the serologic responses to overlapping recombinant fragments of the Pneumocystis jirovecii major surface glycoprotein (Msg) in HIV-infected patients with pneumonia due to P. jirovecii and other causes. Similar baseline geometric mean antibody levels to the fragments measured by an ELISA were found in both groups. Serum antibodies to MsgC in P. jirovecii patients rose to a peak level 3-4 weeks (p<0.001) after recovery from pneumocystosis; baseline CD4+ count > or =50 cells/microL and first episode of pneumocystosis were the principal host factors associated with this rise (both p<0.001). Thus, MsgC shows promise as a serologic reagent and should be tested further in clinical and epidemiologic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.